Jean-Charles Soria: Liquid biopsies offer 2 paths for MRD detection in colorectal cancer, by B. Martínez-Castedo
Jean-Charles Soria, Senior Vice President and Oncology Therapeutic Area Head at Amgen, shared a recent article by on LinkedIn:
“Liquid biopsies offer 2 paths for MRD detection in colorectal cancer:
1) Tumor-Informed: High sensitivity via personalized tumor profiles. Requires tissue sampling.
2) Tumor-Agnostic: Broader use with plasma-only analysis. Lower sensitivity but evolving technology bridges the gap.”
Authors: B. Martínez-Castedo, D.G. Camblor, J. Martín-Arana1, J.A. Carbonell-Asins, B. García-Micó, V. Gambardella, M. Huerta, S. Roselló, D. Roda, F. Gimeno-Valiente, A. Cervantes and N. Tarazona
Jean-Charles Soria serves as Amgen’s senior vice president of Oncology within Global Development. He is a medical oncologist and a professor of medicine at Paris-Saclay University. From 2017 to 2019, he was the senior vice president of Research and Development in Oncology at AstraZeneca. Additionally, Soria has authored or co-authored over 670 articles in leading international journals and has been recognized as one of the world’s most influential research scientists.
More posts featuring Jean-Charles Soria.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023